AbbVie follows Gilead in throwing Xilio a lifeline.

But the overall survival benefit in prostate cancer is still driven by HRR mutations.

The deal isn’t done, but would be Merck’s biggest oncology buy.

Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.

Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.

Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.